Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.53 |
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.53 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30345279 | 1.00 | TLR8 (0.53) | TLR8TLR7NUDT1KDM4EALDH1A1 | |
| SCHEMBL5750404 | 0.90 | TLR8 (0.62) | TLR8TLR7NUDT1 | |
| SCHEMBL14592851 | 0.89 | TLR7 (0.56) | TLR8TLR7 | |
| SCHEMBL29714532 | 0.87 | TLR8 (0.52) | TLR8TLR7NUDT1 | |
| SCHEMBL16904656 | 0.87 | TLR8 (0.52) | TLR8TLR7NUDT1 | |
| SCHEMBL14592760 | 0.85 | TLR7 (0.57) | TLR8TLR7 | |
| SCHEMBL13613799 | 0.85 | TLR7 (0.54) | TLR8TLR7 | |
| SCHEMBL6776089 | 0.84 | CCR3 (0.44) | TLR8TLR7 | |
| SCHEMBL14592777 | 0.84 | TLR7 (0.56) | TLR7 | |
| SCHEMBL5407996 | 0.83 | TLR8 (0.68) | TLR8TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155688-A1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-06-07 | — | — | US | claimed |
| EP-3298131-A1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | The Regents of The University of California (US) | 2018-03-28 | — | — | EP | claimed |
| WO-2016187459-A1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-24 | — | — | WO | claimed |
| US-12201684-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240417738-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION | 2024-12-19 | — | — | US | disclosed |
| US-20240033348-A1 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | Pulmotect, Inc. | 2024-02-01 | — | — | US | disclosed |
| US-20240002799-A1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-04 | — | — | US | disclosed |
| US-11826422-B2 | Methods and compositions for adaptive immune modulation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-28 | — | — | US | disclosed |
| US-11680244-B2 | Method for generating human dendritic cells for immunotherapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-20 | — | — | US | disclosed |
| WO-2023070132-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-3298131-B1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | UNIV CALIFORNIA (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20120128715-A1 | METHOD FOR STIMULATING THE IMMUNE RESPONSE OF NEWBORNS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120082700-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2012-04-05 | — | — | US | disclosed |
| EP-2411521-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | The Board of Regents of The University of Texas System (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20100310606-A1 | VACCINATION WITH KILLED BUT METABOLICALLY ACTIVE (KBMA) PROTOZOANS WITH TOLL-LIKE RECEPTOR AGONISTS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010111485-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-09-30 | — | — | WO | disclosed |
| US-7560436-B2 | Methods of treating gastrointestinal inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-14 | — | — | US | disclosed |
| WO-2009018465-A1 | VACCINATION WITH KILLED BUT METABOLICALLY ACTIVE (KBMA) PROTOZOANS WITH TOLL-LIKE RECEPTOR AGONISTS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080193468-A1 | Method for Stimulating the Immune Response of Newborns | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-08-14 | — | — | US | disclosed |
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | IFNG, IFNAR1, TNF | TLR8 34/4885TLR7 38/4885NUDT1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.